Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Pharmacy Benefit Managers (PBMs)
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 1201 Results
NPC Submits Comments Regarding the Medicare Hospital Outpatient Prospective Payment System
NPC submitted comments to CMS regarding the Medicare Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule for Calendar Year 2025.
NPC Submits Comments to CMS on Proposed Rule on CY 2025 Payment Policies and More
In response to CMS' request for comments, NPC shared its input on the proposed rule for payment policies under the Medicare Physician Fee Schedule for calendar year 2025.
NPC responds to CMS's Information Collection Request on the Negotiation Data Elements and Drug Price Negotiation Process for the Initial Price Applicability Year 2027
NPC offered the agency insights on the data collection requirements it has proposed to inform the second round of the the price-setting efforts in the Medicare Drug Price Negotiation Program.
The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting
NPC’s commentary in AJMC examines evidence regarding the clinical benefit of the FDA’s Accelerated Approval Program and finds it is working for patients.
Analyzing Accelerated Approval for Oncology Drugs: NPC Commentary Evaluates Evidence on FDA Program Effectiveness, Concludes Benefits Outweigh Risks
A new publication in AJMC examines evidence regarding the clinical benefit of the FDA’s Accelerated Approval Program and finds it is working for patients
NPC Submits Comments on Next Steps in the 21st Century Cures Initiative
NPC's comments respond to a Congressional Request for Information soliciting input on opportunities to build on the 21st Century Cures Act.
New Study Sheds Light on Rebate Guarantees and the Role of Employer Benefits Consultants and Brokers in PBM Selection
NPC research published in the American Journal of Managed Care underscores the role employer benefits consultants may play in perpetuating employer reliance on guaranteed rebate arrangements.
Prescription Rebate Guarantees: Employer Insights
Nearly two-thirds of employer drug benefit decision makers reported having rebate agreements with a rebate guarantee for specialty drugs, according to new research from NPC published in the American…
NPC Submits Comments to CMS on Draft Guidance for the Medicare Drug Price Negotiation Program for 2027
In this comment letter, NPC weighs in on CMS' s draft guidance regarding the second cycle of the Medicare Drug Price Negotiation Program.
New Primer Highlights Unanswered Questions and Unintended Consequences of State Prescription Drug Affordability Boards
Four states have given these boards authority to set drug prices. A new Health Affairs Forefront publication highlights the uncertainties, challenges, and unintended consequences for patients amid…
Unanswered Questions and Unintended Consequences of State Prescription Drug Affordability Boards
Four states have given these boards authority to set drug prices. Published in Health Affairs Forefront, this primer highlights the uncertainties, challenges, and unintended consequences for patients…
NPC's John O'Brien Delivers 2024 Hooding Ceremony Address at Washington State University
Dr. John M. O'Brien spoke to graduates of Washington State University's College of Pharmacy and Pharmaceutical Sciences at the hooding ceremony on Thursday, May 9, 2024.